

Irene Litvan,, Faan, Fana

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4064285/irene-litvan-faan-fana-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

379
papers

42,558
citations

90
h-index

203
g-index

407
ext. papers

49,874
ext. citations

6
avg, IF

6.82
L-index

#	Paper	IF	Citations
379	Wearable electrochemical microneedle sensing platform for real-time continuous interstitial fluid monitoring of apomorphine: Toward Parkinson management. <i>Sensors and Actuators B: Chemical</i> , 2022 , 354, 131234	8.5	4
378	Changes in Self- and Informant-Reported Frontal Behaviors in Parkinson's Disease: A Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022 , 35, 89-101	3.8	1
377	Proposed research criteria for prodromal behavioural variant frontotemporal dementia.. <i>Brain</i> , 2022 ,	11.2	1
376	Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 30	9.7	2
375	Internetwork Connectivity Predicts Cognitive Decline in Parkinson's and Is Altered by Genetic Variants.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 853029	5.3	0
374	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 479-483	2.2	0
373	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. <i>Movement Disorders</i> , 2022 ,	7	19
372	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.. <i>Cell Reports Medicine</i> , 2022 , 3, 100607	18	0
371	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , 2021 , 12, 805135	4.1	1
370	Informant-Reported Cognitive Decline is Associated with Objective Cognitive Performance in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 439-449	3.1	1
369	Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2021 , 28, 812-828	2.1	2
368	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2021 , 20, 182-192	24.1	29
367	Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing [I]FP-CIT SPECT/CT Brain Imaging. <i>Tomography</i> , 2021 , 7, 95-106	3.1	0
366	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021 , 7, 16	9.7	2
365	Association of Stress-Health Factors among Parkinson's Disease Patient/Caregiving-Partner Dyads. <i>Archives of Clinical Neuropsychology</i> , 2021 ,	2.7	1
364	TRANSCENDS: A Career Development Program for Underrepresented in Medicine Scholars in Academic Neurology. <i>Neurology</i> , 2021 ,	6.5	2
363	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021 , 28, 1901-1909	6	2

362	Gene-Environment Interactions in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021 , 12, 664796	4.6	1
361	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021 , 96, e2296-e2312	6.5	12
360	Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. <i>Frontiers in Neurology</i> , 2021 , 12, 648532	4.1	6
359	Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021 , 11,	2.3	7
358	Environmental Risk Factors for Progressive Supranuclear Palsy. <i>Journal of Movement Disorders</i> , 2021 , 14, 103-113	2.9	1
357	Hispanic Perspectives on Parkinson's Disease Care and Research Participation. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 809-819	4.3	2
356	A Microstirring Pill Enhances Bioavailability of Orally Administered Drugs. <i>Advanced Science</i> , 2021 , 8, 2100389	13.6	8
355	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. <i>Frontiers in Neurology</i> , 2021 , 12, 571800	4.1	3
354	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. <i>Cortex</i> , 2021 , 139, 99-115	3.8	3
353	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021 , 97, e814-e824	6.5	0
352	Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. <i>Angewandte Chemie - International Edition</i> , 2021 , 60, 19074-19078	16.4	12
351	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. <i>Frontiers in Neurology</i> , 2021 , 12, 694872	4.1	1
350	Brain volumetric deficits in MAPT mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 95-110	5.3	4
349	Delineation of Apathy Subgroups in Parkinson's Disease: Differences in Clinical Presentation, Functional Ability, Health-related Quality of Life, and Caregiver Burden. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 92-99	2.2	1
348	Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1281, 151-176	3.6	2
347	Medication Management Performance in Parkinson's Disease: Examination of Process Errors. <i>Archives of Clinical Neuropsychology</i> , 2021 , 36, 1307-1315	2.7	2
346	The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021 , 80, 210-219	3.1	32
345	Sex differences for phenotype in pathologically defined dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 745-750	5.5	3

344	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , 2021 , 83, 115-122	3.6	3
343	Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. <i>Angewandte Chemie</i> , 2021 , 133, 19222-19226	3.6	4
342	Reply to: "Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?". <i>Movement Disorders</i> , 2021 , 36, 1999-2000	7	
341	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021 , 27, 1451-1457	50.5	16
340	Semantic Recollection in Parkinson's Disease: Functional Reconfiguration and MAPT Variants. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 727057	5.3	1
339	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 926-939	27.4	16
338	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
337	The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042846	1.2	
336	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045482	1.2	
335	Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD). <i>Alzheimer's and Dementia</i> , 2020 , 16, e046247	1.2	
334	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. <i>Neurology</i> , 2020 , 95, e35-e45	6.5	3
333	Pathology-Proven Corticobasal Degeneration Presenting as Richardson's Syndrome. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 267-272	2.2	2
332	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. <i>Alzheimer's and Dementia</i> , 2020 , 16, 118-130	1.2	25
331	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020 , 35, 650-661	7	14
330	Utility of the global CDR plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. <i>Alzheimer's and Dementia</i> , 2020 , 16, 106-117	1.2	27
329	Progressive Supranuclear Palsy and Statin Use. <i>Movement Disorders</i> , 2020 , 35, 1253-1257	7	2
328	Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials. <i>Neurology</i> , 2020 , 94, e2384-e2395	6.5	14
327	Progressive supranuclear palsy: Advances in diagnosis and management. <i>Parkinsonism and Related Disorders</i> , 2020 , 73, 105-116	3.6	17

326	Abnormal distraction and load-specific connectivity during working memory in cognitively normal Parkinson's disease. <i>Human Brain Mapping</i> , 2020 , 41, 1195-1211	5.9	8
325	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020 , 16, 49-59	1.2	17
324	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. <i>Neurology</i> , 2020 , 94, e774-e784	6.5	13
323	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 121-126	3.6	4
322	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 56-60	3.6	4
321	Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 585-596	3.8	2
320	Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. <i>Brain</i> , 2020 , 143, 2868-2871	11.2	3
319	Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report. <i>Clinical Autonomic Research</i> , 2020 , 30, 575-577	4.3	0
318	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 127-132	3.6	3
317	Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 961-964	2.2	1
316	Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. <i>Frontiers in Neurology</i> , 2020 , 11, 897	4.1	8
315	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 750-762	2.2	13
314	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020 , 16, 11-21	1.2	18
313	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2020 , 139, 63-77	14.3	49
312	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , 2020 , 35, 171-176	7	23
311	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020 , 16, 37-48	1.2	18
310	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 449-461	5.3	18
309	α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. <i>Nature Communications</i> , 2020 , 11, 1875	17.4	102

308	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1655-1662	7	8
307	End of life planning in parkinsonian diseases. <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 73-78	3.6	5
306	Treatment of Progressive Supranuclear Palsy. <i>Current Clinical Neurology</i> , 2019 , 137-140	0.1	1
305	The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners. <i>Quality of Life Research</i> , 2019 , 28, 2705-2716	3.7	5
304	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. <i>Lancet Neurology</i> , 2019 , 18, 549-558	24.1	78
303	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 23	9	2
302	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1228-1232	7	56
301	Factor Analysis of the Apathy Scale in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 379-386	2.2	7
300	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019 , 92, 329-337	6.5	144
299	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1218-1228	1.2	20
298	Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. <i>ACS Sensors</i> , 2019 , 4, 2196-2204	9.2	94
297	Hypertension and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 166-170	3.6	7
296	Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019 , 47, 187-197	2.6	10
295	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 87-93	3.6	11
294	Occupation and Parkinson disease in the Women's Health Initiative Observational Study. <i>American Journal of Industrial Medicine</i> , 2019 , 62, 766-776	2.7	1
293	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 34-39	3.6	11
292	Frontrunner in Translation: Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2019 , 10, 1125	4.1	8
291	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 797-808	5.2	5

290	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 138-145	3.6	4
289	The virtual reality of Parkinson's disease freezing of gait: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 26-33	3.6	13
288	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019 , 34, 430-435		21
287	Progress in the treatment of Parkinson-Plus syndromes. <i>Parkinsonism and Related Disorders</i> , 2019 , 59, 101-110	3.6	4
286	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. <i>Movement Disorders</i> , 2018 , 33, 468-472	7	11
285	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018 , 33, 503-510	7	33
284	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018 , 33, 520-527	7	10
283	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 501-502	7	0
282	Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 349-361	5.9	14
281	Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans. <i>Frontiers in Neurology</i> , 2018 , 9, 474	4.1	14
280	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
279	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
278	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. <i>Neurodegenerative Diseases</i> , 2018 , 18, 173-190	2.3	8
277	Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress. <i>Human Molecular Genetics</i> , 2018 , 27, 3951-3963	5.6	24
276	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018 , 13, e0201964	3.7	21
275	Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 387-394	6	6
274	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. <i>Acta Neuropathologica</i> , 2018 , 136, 389-404	14.3	27
273	Anti-inflammatory drug use and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018 , 48, 89-92	3.6	5

272	Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 99-100	2.2	0
271	P1-433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC MAPT MUTATION CARRIERS 2018 , 14, P475-P476		
270	Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 331	5.3	3
269	Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1539-1548	4.3	2
268	Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. <i>Neurology</i> , 2018 , 91, 797-799	6.5	16
267	Does the Geriatric Depression Scale measure depression in Parkinson's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1662-1670	3.9	9
266	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018 , 33, 1750-1759	7	22
265	Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 717-723	2.2	6
264	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017 , 32, 995-1005	7	88
263	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017 , 32, 955-971	7	127
262	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
261	Therapeutic options for Progressive Supranuclear Palsy including investigational drugs. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 575-587	1.1	5
260	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017 , 32, 1056-1065	7	75
259	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , 2017 , 16, 552-563	24.1	209
258	Levodopa-Responsive Parkinsonism Associated with Giant Virchow-Robin Spaces: A Case Report. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 619-622	2.2	3
257	Understanding falls in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017 , 35, 75-83	16	8
256	Genetic influences on cognition in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017 , 32, 1764-1771		5
255	F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017 , 82, 622-634	9.4	106

254	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 279-289	6.5	24
253	[O21701]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER'S DISEASE 2017 , 13, P599-P600		9
252	The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 377-383	5.3	3
251	Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions. <i>Sensors</i> , 2017 , 17,	3.8	61
250	Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 197	5.3	19
249	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017 , 12, e0175674	3.7	84
248	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. <i>Neurology</i> , 2016 , 87, 2016-2025	6.5	45
247	Cognitive functioning in individuals with Parkinson's disease and traumatic brain injury: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2016 , 30, 58-61	3.6	5
246	The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. <i>Acta Neuropathologica</i> , 2016 , 131, 75-86	14.3	524
245	Progressive supranuclear palsy: progression and survival. <i>Journal of Neurology</i> , 2016 , 263, 380-389	5.5	33
244	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016 , 25, 81-8	3.7	14
243	Environmental Exposures and Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2016 , 13,	4.6	102
242	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. <i>PLoS ONE</i> , 2016 , 11, e0157218	3.7	33
241	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-827		305
240	Synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016 , 79, 991-9	9.4	64
239	Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. <i>Movement Disorders</i> , 2016 , 31, 644-52	7	36
238	Relationship between uric acid levels and progressive supranuclear palsy. <i>Movement Disorders</i> , 2016 , 31, 663-7	7	8
237	Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. <i>Cogent Psychology</i> , 2016 , 3, 1131476	1	11

236	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology, The</i> , 2016 , 15, 546-8	24.1	61
235	Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 54-60	3.6	17
234	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016 , 31, 1623-1627		35
233	Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 65-67	2.2	3
232	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Communications</i> , 2015 , 6, 7247	17.4	118
231	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2015 , 36, 1605.e7-12	5.6	70
230	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 919-27	7	179
229	Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 253-265	1.1	6
228	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1600-11	7	645
227	The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2015 , 10, 50	19	60
226	Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 971-81	5.3	12
225	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 127-134	2.2	14
224	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1591-601	7	2371
223	Swallowing disturbances in the corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1342-8	3.6	9
222	The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World. <i>Lecture Notes in Computer Science</i> , 2015 , 412-422	0.9	4
221	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014 , 29, 470-8	7	201
220	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014 , 46, 989-93	36.3	1261
219	A disposable electrochemical biosensor for l-DOPA determination in undiluted human serum. <i>Electrochemistry Communications</i> , 2014 , 48, 28-31	5.1	17

218	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 454-62	7	290
217	Correcting for demographic variables on the modified telephone interview for cognitive status. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 1438-43	6.5	5
216	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , 2014 , 13, 676-85	24.1	197
215	The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 627-31	3.6	33
214	Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 503-7	3.6	27
213	Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of multiple system atrophy. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 693-8	5.3	3
212	Instrumental activities of daily living are impaired in Parkinson's disease patients with mild cognitive impairment. <i>Neuropsychology</i> , 2014 , 28, 229-37	3.8	58
211	Parkinson's disease mild cognitive impairment: application and validation of the criteria. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 131-7	5.3	42
210	Corticobasal degeneration. <i>Seminars in Neurology</i> , 2014 , 34, 160-73	3.2	41
209	Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinson's Disease. <i>Timing and Time Perception</i> , 2014 , 2, 145-168	0.7	14
208	Rate of decline in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014 , 29, 463-8	7	26
207	Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 360-7	7	44
206	Cognition in movement disorders: where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014 , 29, 704-11	7	13
205	Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). <i>Pharmacotherapy</i> , 2014 , 34, 1250-8	5.8	34
204	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. <i>JAMA Neurology</i> , 2014 , 71, 543-52	17.2	239
203	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 31	7.3	104
202	The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 463-5	3.6	0
201	Long-duration Parkinson's disease: role of lateralization of motor features. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 77-80	3.6	28

200	Behavioral abnormalities in progressive supranuclear palsy. <i>Psychiatry Research</i> , 2013 , 210, 1205-10	9.9	82
199	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013 , 80, 496-503	6.5	1004
198	Measuring mild cognitive impairment in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 626-33	7	98
197	White-matter changes correlate with cognitive functioning in Parkinson's disease. <i>Frontiers in Neurology</i> , 2013 , 4, 37	4.1	40
196	Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. <i>Archives of Clinical Neuropsychology</i> , 2013 , 28, 104-13	2.7	63
195	Parkinsonian syndromes. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013 , 19, 1189-212	3	45
194	Functional impairment in progressive supranuclear palsy. <i>Neurology</i> , 2013 , 80, 380-4	6.5	12
193	Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 67-75	2.6	36
192	Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013 , 35, 926-33	2.1	23
191	Primary health care providers' knowledge gaps on Parkinson's disease. <i>Educational Gerontology</i> , 2013 , 39, 856-862	1.2	2
190	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
189	Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines. <i>Movement Disorders</i> , 2012 , 27, 1707-1707	7	2
188	Brain-lung-thyroid disease: clinical features of a kindred with a novel thyroid transcription factor 1 mutation. <i>Journal of Child Neurology</i> , 2012 , 27, 68-73	2.5	7
187	Annonacin in <i>Asimina triloba</i> fruit: implication for neurotoxicity. <i>NeuroToxicology</i> , 2012 , 33, 53-8	4.4	38
186	Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. <i>BMC Medical Genetics</i> , 2012 , 13, 16	2.1	3
185	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012 , 27, 1308-11	7	14
184	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. <i>Annals of Neurology</i> , 2012 , 71, 370-84	9.4	214
183	Phosphorylated β -synuclein in Parkinson's disease. <i>Science Translational Medicine</i> , 2012 , 4, 121ra20	17.5	182

182	Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 343-52	2.5	30
181	Examining the motor phenotype of patients with both essential tremor and Parkinson's disease. <i>Tremor and Other Hyperkinetic Movements</i> , 2012 , 2,	2	8
180	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011 , 43, 699-705	36.3	386
179	Cytokine expression and microglial activation in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 683-8	3.6	51
178	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011 , 7, e60-e76	1.2	59
177	Parkinsonism and frontotemporal dementia: the clinical overlap. <i>Journal of Molecular Neuroscience</i> , 2011 , 45, 343-9	3.3	39
176	Milestones in atypical and secondary Parkinsonisms. <i>Movement Disorders</i> , 2011 , 26, 1083-95	7	58
175	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527
174	Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 751-3	5.5	13
173	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. <i>Brain</i> , 2011 , 134, 3264-75	11.2	87
172	Copy number variation in familial Parkinson disease. <i>PLoS ONE</i> , 2011 , 6, e20988	3.7	53
171	A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 423-6	3.6	48
170	Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 535-9	3.6	29
169	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 1077-81	7	90
168	H1/H1 genotype influences symptom severity in corticobasal syndrome. <i>Movement Disorders</i> , 2010 , 25, 760-3	7	6
167	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 2501-7	7	124
166	Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. <i>Neurology</i> , 2009 , 73, 1469-77	6.5	114
165	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , 2009 , 8, 1150-7	24.1	567

164	Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. <i>Lancet Neurology, The</i> , 2009 , 8, 1128-39	24.1	528
163	Reply: Corticobasal syndrome with Alzheimer's disease pathology. <i>Movement Disorders</i> , 2009 , 24, 153-153		
162	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. <i>Human Genetics</i> , 2009 , 124, 593-605	6.3	363
161	Genomewide association study for onset age in Parkinson disease. <i>BMC Medical Genetics</i> , 2009 , 10, 98	2.1	78
160	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009 , 16, 297-309	6	143
159	Parkinson's Disease: An Overview of Pathogenesis 2009 , 159-178		
158	The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. <i>BMC Medicine</i> , 2008 , 6, 32	11.4	72
157	Clinical symptoms in Alzheimer's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 207-16	3	13
156	Neuropathology of Pick body disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 415-30	3	9
155	The Epidemiology of vascular dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 639-58	3	12
154	Biology and neuropathology of dementia in syphilis and Lyme disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 825-44	3	26
153	Perspectives of Alzheimer's disease treatments. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 273-90	3	1
152	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 671-86	3	6
151	Clinical aspects and biology of normal pressure hydrocephalus. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 887-902	3	9
150	The neuropathology of vascular and mixed dementia and vascular cognitive impairment. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 687-703	3	6
149	Clinical aspects of Parkinson dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 303-6	3	
148	Current and future therapeutic approaches in progressive supranuclear palsy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 493-508	3	6
147	Clinical and therapeutic aspects of dementia in syphilis and Lyme disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 819-23	3	3

146	Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. <i>Neurology</i> , 2008 , 71, 28-34	6.5	90
145	History of dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 3-13	3	1
144	Quality of life in dementias. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 97-100	3	3
143	Neuropathology and genetics of corticobasal degeneration. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 523-32	3	2
142	Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 393-414	3	9
141	Progressive supranuclear palsy and corticobasal degeneration: similarities and differences. <i>Future Neurology</i> , 2008 , 3, 299-307	1.5	
140	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. <i>Human Genetics</i> , 2008 , 124, 95-9	6.3	28
139	Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. <i>Movement Disorders</i> , 2008 , 23, 1596-601	7	7
138	Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). <i>Annals of Neurology</i> , 2008 , 63, 295-302	9.4	291
137	Is it PD, PSP, CBD, DLB, or MSA? 2008 , 219-222		
136	Neurobiology of Progressive Supranuclear Palsy 2007 , 105-110		
135	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1689-707; quiz 1837	7	1968
134	Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007 , 22, 2314-24	7	708
133	Update of atypical Parkinsonian disorders. <i>Current Opinion in Neurology</i> , 2007 , 20, 434-7	7.1	5
132	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 251-7	3.1	88
131	The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 329-36	3.1	38
130	Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. <i>American Journal of Human Genetics</i> , 2007 , 80, 769-78	11	61
129	Unraveling progressive supranuclear palsy: from the bedside back to the bench. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S341-6	3.6	18

128	Current and future treatments in progressive supranuclear palsy. <i>Current Treatment Options in Neurology</i> , 2006 , 8, 211-23	4.4	17
127	Alzheimer's disease presenting as corticobasal syndrome. <i>Movement Disorders</i> , 2006 , 21, 2018-22	7	53
126	Lrrk2 and Lewy body disease. <i>Annals of Neurology</i> , 2006 , 59, 388-93	9.4	237
125	Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. <i>Archives of Neurology</i> , 2006 , 63, 826-32		131
124	Measuring quality of life in PSP: the PSP-QoL. <i>Neurology</i> , 2006 , 67, 39-44	6.5	53
123	Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. <i>Neurology</i> , 2006 , 66, 949-50	6.5	59
122	Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. <i>Neurology</i> , 2006 , 67, 2206-10	6.5	33
121	BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. <i>Neurology</i> , 2005 , 65, 1823-5	6.5	58
120	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. <i>Neurology</i> , 2005 , 65, 1863-72	6.5	3921
119	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. <i>Movement Disorders</i> , 2005 , 20, 982-8	7	100
118	"Applause sign" helps to discriminate PSP from FTD and PD. <i>Neurology</i> , 2005 , 64, 2132-3	6.5	100
117	Progressive Supranuclear Palsy 2005 , 287-308		5
116	What is an Atypical Parkinsonian Disorder? 2005 , 1-9		5
115	Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. <i>Neurocase</i> , 2005 , 11, 250-62	0.8	16
114	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005 , 14, 3281-92	5.6	144
113	Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. <i>Brain</i> , 2005 , 128, 570-83	11.2	144
112	Progressive Supranuclear Palsy and Corticobasal Degeneration 2005 , 505-514		1
111	Diagnostic issues in non-AD dementias. <i>Clinical Neuroscience Research</i> , 2004 , 3, 363-374		1

110	Update on progressive supranuclear palsy. <i>Current Neurology and Neuroscience Reports</i> , 2004 , 4, 296-302	6.6	29
109	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. <i>NeuroImage</i> , 2004 , 21, 714-24	7.9	135
108	ATYPICAL PARKINSONIAN DISORDERS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2004 , 10, 42-64	3	
107	Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees. <i>Lecture Notes in Computer Science</i> , 2004 , 1018-1024	0.9	
106	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003 , 60, 917-22	6.5	90
105	Update on epidemiological aspects of progressive supranuclear palsy. <i>Movement Disorders</i> , 2003 , 18 Suppl 6, S43-50	7	114
104	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003 , 54 Suppl 5, S15-9	9.4	423
103	Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?. <i>European Journal of Neurology</i> , 2003 , 10, 103-6	6	18
102	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 1215-20	5.5	163
101	Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Movement Disorders</i> , 2002 , 17, 1041-5	7	39
100	Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002 , 61, 935-46	3.1	462
99	Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. <i>European Journal of Neurology</i> , 2001 , 8, 707-10	6	55
98	Impairment of eyeblink classical conditioning in progressive supranuclear palsy. <i>Movement Disorders</i> , 2001 , 16, 240-51	7	10
97	Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. <i>Movement Disorders</i> , 2001 , 16, 1098-104	7	36
96	Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. <i>BMC Neurology</i> , 2001 , 1, 3	3.1	50
95	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001 , 56, 1702-6	6.5	358
94	Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. <i>Archives of Neurology</i> , 2001 , 58, 259-64		291
93	Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy. <i>Neurology</i> , 2001 , 57, 138-40	6.5	33

92	Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. <i>Neurology</i> , 2001 , 56, 957-63	6.5	75
91	Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. <i>Neurology</i> , 2001 , 57, 467-73	6.5	137
90	Diagnosis and management of progressive supranuclear palsy. <i>Seminars in Neurology</i> , 2001 , 21, 41-8	3.2	50
89	An open letter to the Committee on The Nobel Prize in Medicine. <i>Parkinsonism and Related Disorders</i> , 2001 , 7, 149-55	3.6	7
88	Therapy and management of frontal lobe dementia patients. <i>Neurology</i> , 2001 , 56, S41-5	6.5	27
87	Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 42-9	2.7	104
86	Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. <i>Journal of Neurochemistry</i> , 2000 , 75, 1681-4	6	66
85	Research goals in progressive supranuclear palsy. <i>Movement Disorders</i> , 2000 , 15, 446-458	7	26
84	Language disturbances in corticobasal degeneration. <i>Neurology</i> , 2000 , 54, 990-2	6.5	68
83	Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. <i>Neurology</i> , 2000 , 54, 1029-32	6.5	127
82	The FAB: a Frontal Assessment Battery at bedside. <i>Neurology</i> , 2000 , 55, 1621-6	6.5	2701
81	Pupillary diameter assessment: need for a graded scale. <i>Neurology</i> , 2000 , 54, 530-1	6.5	45
80	Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. <i>Neurology</i> , 2000 , 55, 888-91	6.5	92
79	Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. <i>Neurology</i> , 1999 , 53, 1910-21	6.5	106
78	Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 620-3	5.5	134
77	Association of an extended haplotype in the tau gene with progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 1999 , 8, 711-5	5.6	677
76	Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study. <i>Dysphagia</i> , 1999 , 14, 165-8	3.7	27
75	Ideomotor apraxia in progressive supranuclear palsy: a case study. <i>Movement Disorders</i> , 1999 , 14, 162-6	7	9

74	Progression of falls in postmortem-confirmed parkinsonian disorders. <i>Movement Disorders</i> , 1999 , 14, 947-50	7	122
73	Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. <i>Neurology</i> , 1999 , 53, 1292-9	6.5	191
72	Atypical parkinsonism in the French West Indies. <i>Lancet, The</i> , 1999 , 354, 1472-3	40	1
71	Importance of deficits in executive functions. <i>Lancet, The</i> , 1999 , 354, 1921-3	40	112
70	Clinicopathologic case report. Dementia with Lewy bodies (DLB). <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999 , 11, 107-12	2.7	
69	A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. <i>Neurology</i> , 1999 , 52, 404-6	6.5	8
68	Recent advances in atypical parkinsonian disorders. <i>Current Opinion in Neurology</i> , 1999 , 12, 441-6	7.1	31
67	Dysfunction of Ib (autogenic) spinal inhibition in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 1998 , 13, 668-72	7	11
66	Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. <i>Journal of Neural Transmission</i> , 1998 , 105, 217-27	4.3	44
65	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clinical Autonomic Research</i> , 1998 , 8, 359-62	4.3	248
64	Limb shaking in multiple system atrophy. <i>European Journal of Neurology</i> , 1998 , 5, 113-115	6	
63	Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <i>European Journal of Neurology</i> , 1998 , 5, 451-457	6	35
62	Methodological and research issues in the evaluation of biological diagnostic markers for Alzheimer's disease. <i>Neurobiology of Aging</i> , 1998 , 19, 121-3	5.6	6
61	Is EEG useful in the differential diagnosis of parkinsonism?. <i>Parkinsonism and Related Disorders</i> , 1998 , 4, 79-80	3.6	5
60	Progressive supranuclear palsy: a survey of the disease course. <i>Neurology</i> , 1998 , 50, 1637-47	6.5	100
59	Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 64, 184-9	5.5	229
58	Parkinsonian features: when are they Parkinson disease?. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 280, 1654-5	27.4	13
57	Apathy is not depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1998 , 10, 314-9	2.7	437

56	Clinical and genetic aspects of progressive supranuclear palsy. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998 , 11, 107-14	3.8	26
55	Neuropsychiatric features of corticobasal degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 65, 717-21	5.5	110
54	Pharmacological therapy in progressive supranuclear palsy. <i>Archives of Neurology</i> , 1998 , 55, 1099-102		93
53	Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. <i>Archives of Neurology</i> , 1998 , 55, 969-78		278
52	Progressive supranuclear gaze palsy is in linkage disequilibrium with the tau and not the alpha-synuclein gene. <i>Neurology</i> , 1998 , 50, 270-3	6.5	120
51	Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. <i>Archives of Neurology</i> , 1998 , 55, 1313-9		103
50	PROGRESSIVE SUPRANUCLEAR PALSY. <i>Neurologist</i> , 1998 , 4, 13-20	1.6	3
49	Caregiving in progressive supranuclear palsy. <i>Neurology</i> , 1998 , 51, 1303-9	6.5	26
48	Apolipoprotein E4 (epsilon) allele does not affect the onset or symptom severity in progressive supranuclear palsy. <i>Archives of Neurology</i> , 1998 , 55, 752-4		10
47	Characterizing swallowing abnormalities in progressive supranuclear palsy. <i>Neurology</i> , 1997 , 48, 1654-62	6.5	75
46	Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. <i>Brain</i> , 1997 , 120 (Pt 9), 1541-52	11.2	107
45	What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. <i>Archives of Neurology</i> , 1997 , 54, 937-44		194
44	The clinical and pathologic hallmarks of progressive supranuclear palsy. <i>Current Opinion in Neurology</i> , 1997 , 10, 346-50	7.1	16
43	What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. <i>Neurology</i> , 1997 , 49, 62-9	6.5	73
42	Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. <i>Neurology</i> , 1997 , 48, 119-25	6.5	391
41	Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. <i>Brain</i> , 1997 , 120 (Pt 1), 65-74	11.2	114
40	Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. <i>Journal of Neural Transmission</i> , 1997 , 104, 845-65	4.3	37
39	Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?. <i>Neurology</i> , 1996 , 47, 1324-6	6.5	22

38	Reliability of the NINDS Myotatic Reflex Scale. <i>Neurology</i> , 1996 , 47, 969-72	6.5	69
37	Visualizing cortical activation during mental calculation with functional MRI. <i>NeuroImage</i> , 1996 , 3, 97-103	7.9	167
36	Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. <i>Neurology</i> , 1996 , 47, 1-9	6.5	2130
35	Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). <i>Neurology</i> , 1996 , 46, 922-30	6.5	338
34	Neuropsychiatric aspects of progressive supranuclear palsy. <i>Neurology</i> , 1996 , 47, 1184-9	6.5	208
33	Preserved cognitive processes in cerebellar degeneration. <i>Behavioural Brain Research</i> , 1996 , 79, 131-5	3.4	39
32	What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?. <i>Brain</i> , 1996 , 119 (Pt 3), 831-9	11.2	10
31	Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996 , 55, 97-105	3.1	311
30	Progressive supranuclear palsy: a clinicopathological study of 21 cases. <i>Acta Neuropathologica</i> , 1996 , 91, 427-31	14.3	64
29	Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 60, 615-20	5.5	268
28	A reappraisal of reliability and validity studies in stroke. <i>Stroke</i> , 1996 , 27, 2331-6	6.7	101
27	What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?. <i>Neurology</i> , 1995 , 45, 387-9	6.5	7
26	Neuropsychological features of progressive supranuclear palsy. <i>Brain and Cognition</i> , 1995 , 28, 311-20	2.7	55
25	Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. <i>Annals of Neurology</i> , 1994 , 36, 55-61	9.4	48
24	Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). <i>Neurology</i> , 1994 , 44, 2015-9	6.5	563
23	Cerebellar cognition. <i>Neurology</i> , 1993 , 43, 2153-2153	6.5	2
22	Cognitive planning deficit in patients with cerebellar atrophy. <i>Neurology</i> , 1992 , 42, 1493-6	6.5	370
21	CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy. <i>Acta Neuropathologica Scandinavica</i> , 1992 , 86, 204-6	3.8	5

20	Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991 , 54, 25-9	5.5	78
19	Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991 , 54, 832-5	5.5	12
18	Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. <i>Neurology</i> , 1991 , 41, 1257-62	6.5	25
17	Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. <i>Canadian Journal of Neurological Sciences</i> , 1990 , 17, 292-7	1	33
16	Implicit learning in patients with Alzheimer's disease. <i>Pharmacopsychiatry</i> , 1990 , 23, 94-101	2	76
15	Frontal lobe function in progressive supranuclear palsy. <i>Archives of Neurology</i> , 1990 , 47, 553-8		103
14	Selective deficits in cognition and memory in high-functioning parkinsonian patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990 , 53, 603-6	5.5	53
13	Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. <i>Archives of Neurology</i> , 1990 , 47, 1346-50		31
12	Memory impairment in patients with progressive supranuclear palsy. <i>Archives of Neurology</i> , 1989 , 46, 765-7		51
11	Physostigmine treatment of progressive supranuclear palsy. <i>Annals of Neurology</i> , 1989 , 26, 404-7	9.4	36
10	Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease. <i>Developmental Neuropsychology</i> , 1988 , 4, 295-302	1.8	1
9	Slowed information processing in multiple sclerosis. <i>Archives of Neurology</i> , 1988 , 45, 281-5		188
8	Multiple memory deficits in patients with multiple sclerosis. Exploring the working memory system. <i>Archives of Neurology</i> , 1988 , 45, 607-10		137
7	Behçet's syndrome masquerading as tumor. <i>Neuroradiology</i> , 1987 , 29, 103	3.2	15
6	Does reversed laterality really exist in dextrals? A case study. <i>Neuropsychologia</i> , 1986 , 24, 241-54	3.2	15
5	Neuropsychiatric and cognitive disorders in other parkinsonian disorders261-274		2
4	Woman with gait impairment and difficulty reading229-237		
3	Measuring quality of life in progressive supranuclear palsy52-59		1

2 Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration 11

1 Progressive Supranuclear Palsy and Corticobasal Degeneration 135-155 27